Chimeric Peptides Inhibit JNK Signaling for Cystitis Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current JNK signaling pathway inhibitors are limited in their application to only a few diseases, and there is a need for new JNK inhibitor peptides that can target a broader range of diseases related to JNK signaling, including cystitis.
Innovation Solution
Development of chimeric peptides comprising a trafficking sequence and a JNK inhibitor sequence, specifically designed to inhibit JNK signaling pathway, which can be administered intravesically for treating cystitis and other inflammatory or non-inflammatory diseases related to JNK signaling.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Adaptability or versatility
If existing JNK signaling pathway inhibitors are used, then JNK activity is inhibited, but the application is limited to only a few diseases
Solution Approach 1:
The patent develops chimeric peptides that can inhibit JNK signaling pathway across multiple disease types including cystitis, neurological disorders, and inflammatory conditions. The peptides are designed with universal applicability to various JNK-related pathologies while maintaining reliable inhibition through optimized peptide sequences and structures
2Adaptability or versatility
If new JNK inhibitor peptides are developed for broader disease treatment, then disease coverage is expanded, but the number of known effective inhibitors increases
Solution Approach 1:
The patent segments the JNK inhibitor development into specific chimeric peptide designs with defined sequences and structures. Each peptide is engineered as a discrete molecular entity with specific amino acid compositions, allowing systematic exploration of different inhibitor types while maintaining manageable complexity through structured design approaches
3Ease of operation
If chimeric peptides with trafficking sequences are designed, then cell permeability is improved, but peptide structure complexity increases
Solution Approach 1:
The patent merges the JNK inhibitor sequence with a trafficking sequence to create a single chimeric peptide molecule. This combination allows the peptide to simultaneously inhibit JNK signaling and penetrate cell membranes, achieving both therapeutic function and cellular delivery in one integrated structure
4Reliability
If intravesical administration is used for cystitis treatment, then local efficacy is improved, but systemic availability is reduced
Solution Approach 1:
The patent applies intravesical administration to deliver the chimeric peptide directly to the bladder tissue where cystitis occurs. This local delivery approach concentrates the therapeutic agent at the site of infection, maximizing local efficacy while minimizing systemic exposure and potential side effects
Data Source
Figure 1A~1C
Figure 2
Figure 3a~3d
AI summary
The present invention refers to the use of protein kinase inhibitors and more specifically to the use of inhibitors of the protein kinase c-Jun amino terminal kinase, JNK inhibitor sequences, chimeric peptides, or of nucleic acids encoding same as well as pharmaceutical compositions containing same, for the treatment of various diseases or disorders strongly related to JNK signaling.